Increased Cancer Risk & Effectiveness Concerns Prompt EU-Wide Review Of Preterm Birth Medicine
Executive Summary
The European Medicines Agency is re-examining the benefits and risks of hydroxyprogesterone medicines for gynecologic and obstetrical conditions at the request of the French regulator ANSM.
You may also be interested in...
Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More
Short stories about how US FDA’s conference center changed since COVID-19 forced the end of in-person public events, what the agency did to officially close the books on Makena, and more.
Makena: Professional Societies Finally See Eye To Eye With US FDA’s Drugs Center
After two decades of recommending use of intramuscular 17-OHPC to prevent preterm birth, the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine revised their clinical guidelines in the wake of the FDA’s order withdrawing Covis’ Makena and its generics.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.